STRATA Skin Sciences Reports Strong Third Quarter 2022 Financial Results
November 09, 2022 16:05 ET
|
STRATA Skin Sciences, Inc.
Strong revenue in the third quarter 2022 of $9.4 million, a 22% increase over the third quarter of 2021Strong international sales of $3.3 million, an 82% increase over the third quarter of...
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
November 08, 2022 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
STRATA Skin Sciences to Report Third Quarter 2022 Financial Results on November 9, 2022
October 26, 2022 16:05 ET
|
STRATA Skin Sciences, Inc.
HORSHAM, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for...
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
October 21, 2022 08:35 ET
|
Novan, Inc.
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced...
EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®
October 21, 2022 08:35 ET
|
Novan, Inc.
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced that...
Interim Results of MATCH Study Demonstrate Improved Decision Making and Clinical Outcomes When Using Mind.Px™ to Determine Biologic Drug Class for Psoriasis Patients
October 20, 2022 08:00 ET
|
Mindera Health
San Diego, CA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interim clinical utility and patient outcomes data regarding Mindera Health’s Mind.Px™ test from the ongoing MATCH study were recently presented at...
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
October 14, 2022 08:30 ET
|
Novan, Inc.
DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been accepted for...
With 8.7% CAGR, Psoriasis Treatment Market Size worth USD 47.24 billion by [2022-2029]
October 07, 2022 07:31 ET
|
Fortune Business Insights
Pune, India, Oct. 07, 2022 (GLOBE NEWSWIRE) -- The psoriasis treatment market size was USD 24.33 billion in 2021. The market is projected to grow from USD 26.37 billion in 2022 to USD 47.24 billion...
$11+ Billion Dermatology Devices Market Size to Grow at 11.2% CAGR, Globally, by 2028 - Growing Prevalence of Skin Cancers and Skin Disorders
September 30, 2022 08:00 ET
|
The Insight Partners
New York, Sept. 30, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Dermatology Devices Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast...
EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference
September 15, 2022 08:00 ET
|
Novan, Inc.
– New data analysis from previously completed successful Phase 3 study1 demonstrated WYNZORA® Cream to be effective and convenient for skin of color patients for the treatment of plaque psoriasis ...